1.12

0.88% -0.010

After Hours: 1.12

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is traded at $1.12, with a volume of 757.05K. It is down -0.88% in the last 24 hours and down -3.45% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Previous Close:

$1.13

Open:

$1.13

24h Volume:

757.05K

Relative Volume:

1.56

Market Cap:

$69.35M

Revenue:

$248.00K

Net Income/Loss:

$-113.22M

P/E Ratio:

-0.6082

EPS:

-1.8416

Net Cash Flow:

$-98.81M

1W Performance:

-4.27%

1M Performance:

-3.45%

6M Performance:

-15.15%

1Y Performance:

-20.00%

1-Day Range:

$1.105

$1.15

1-Week Range:

$1.105

$1.18

52-Week Range:

$1.09

$1.95

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1095)

Industry

Biotechnology (614)

Phone

650-481-6770

Address

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

PLRX's Discussions on Twitter

Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRX Pliant Therapeutics Inc	1.12	69.97M	248.00K	-113.22M	-98.81M	-1.8416
VRTX Vertex Pharmaceuticals Inc	485.39	126.01B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	70.03B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	56.56B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	40.63B	742.00K	-1.37B	-1.07B	-7.0731

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
Mar-04-25	Resumed	Cantor Fitzgerald	Neutral
Mar-04-25	Downgrade	Needham	Buy → Hold
Mar-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-10-25	Downgrade	Canaccord Genuity	Buy → Hold
Feb-10-25	Downgrade	Citigroup	Buy → Neutral
Feb-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-10-25	Downgrade	JP Morgan	Overweight → Neutral
Feb-10-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-10-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-10-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-09-24	Resumed	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

Jul 09, 2026

Price to earnings forward of Pliant Therapeutics, Inc. – TRADEGATE:9PT - TradingView

Jul 09, 2026

Jul 05, 2026

Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView

Jul 05, 2026

Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – GETTEX:9PT - TradingView

Jul 05, 2026

Jun 29, 2026

PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 29, 2026

Jun 26, 2026